|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for PLA2G16 |
 Gene summary |
| Basic gene Info. | Gene symbol | PLA2G16 |
| Gene name | phospholipase A2, group XVI | |
| Synonyms | AdPLA|H-REV107-1|HRASLS3|HREV107|HREV107-1|HREV107-3|HRSL3 | |
| Cytomap | UCSC genome browser: 11q12.3 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001128203.1, NM_007069.3, | |
| Description | Ca-independent phospholipase A1/2H-rev 107 protein homologHRAS-like suppressor 1HRAS-like suppressor 3adipose-specific PLA2adipose-specific phospholipase A2group XVI phospholipase A1/A2group XVI phospholipase A2renal carcinoma antigen NY-REN-65 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 613867 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000176485 | ||
| HPRD : 13671 | ||
| Protein | UniProt: P53816 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_PLA2G16 | |
| BioGPS: 11145 | ||
| Pathway | NCI Pathway Interaction Database: PLA2G16 | |
| KEGG: PLA2G16 | ||
| REACTOME: PLA2G16 | ||
| Pathway Commons: PLA2G16 | ||
| Context | iHOP: PLA2G16 | |
| ligand binding site mutation search in PubMed: PLA2G16 | ||
| UCL Cancer Institute: PLA2G16 | ||
| Assigned class in mutLBSgeneDB | C: This gene just belongs to mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0006644 | phospholipid metabolic process | 20100577 |
| Top |
| Ligand binding site mutations for PLA2G16 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | C113 | C113F | STAD | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for PLA2G16 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | C113 | C113F | -0.31544782 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for PLA2G16 from PDB |
| Top |
| Differential gene expression and gene-gene network for PLA2G16 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for PLA2G16 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for PLA2G16 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of PLA2G16 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS |
| Top |
| Conservation information for LBS of PLA2G16 |
| Multiple alignments for P53816 in multiple species |
| LBS | AA sequence | # species | Species | C113 | LTSENCEHFVN | 3 | Homo sapiens, Mus musculus, Rattus norvegicus | H23 | RPFYRHWAIYV | 1 | Homo sapiens | H23 | RPMYRHWAIYV | 1 | Mus musculus | H23 | RPMYSHWAIYV | 1 | Rattus norvegicus | L108 | EVLYRLTSENC | 2 | Mus musculus, Rattus norvegicus | L108 | EVLYKLTSENC | 1 | Homo sapiens | T109 | VLYRLTSENCE | 2 | Mus musculus, Rattus norvegicus | T109 | VLYKLTSENCE | 1 | Homo sapiens | W24 | PFYRHWAIYVG | 1 | Homo sapiens | W24 | PMYRHWAIYVG | 1 | Mus musculus | W24 | PMYSHWAIYVG | 1 | Rattus norvegicus | Y21 | IFRPFYRHWAI | 1 | Homo sapiens | Y21 | IFRPMYRHWAI | 1 | Mus musculus | Y21 | IFRPMYSHWAI | 1 | Rattus norvegicus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |